JP2021511047A - 無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス - Google Patents

無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス Download PDF

Info

Publication number
JP2021511047A
JP2021511047A JP2020539779A JP2020539779A JP2021511047A JP 2021511047 A JP2021511047 A JP 2021511047A JP 2020539779 A JP2020539779 A JP 2020539779A JP 2020539779 A JP2020539779 A JP 2020539779A JP 2021511047 A JP2021511047 A JP 2021511047A
Authority
JP
Japan
Prior art keywords
itr
sequence
sense
expression cassette
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020539779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511047A5 (https=
Inventor
オザン アルカン，
オザン アルカン，
ロバート マイケル コーティン，
ロバート マイケル コーティン，
マシュー スタントン，
マシュー スタントン，
ダグラス アンソニー カー，
ダグラス アンソニー カー，
キャロライン ペレティエ，
キャロライン ペレティエ，
Original Assignee
ジェネレーション バイオ カンパニー
ジェネレーション バイオ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネレーション バイオ カンパニー, ジェネレーション バイオ カンパニー filed Critical ジェネレーション バイオ カンパニー
Publication of JP2021511047A publication Critical patent/JP2021511047A/ja
Publication of JP2021511047A5 publication Critical patent/JP2021511047A5/ja
Priority to JP2023116157A priority Critical patent/JP2023126487A/ja
Priority to JP2025084944A priority patent/JP2025113389A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/103—Plasmid DNA for invertebrates
    • C12N2800/105—Plasmid DNA for invertebrates for insects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020539779A 2018-01-19 2019-01-18 無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス Pending JP2021511047A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023116157A JP2023126487A (ja) 2018-01-19 2023-07-14 無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス
JP2025084944A JP2025113389A (ja) 2018-01-19 2025-05-21 無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862619392P 2018-01-19 2018-01-19
US62/619,392 2018-01-19
PCT/US2019/014122 WO2019143885A1 (en) 2018-01-19 2019-01-18 Closed-ended dna vectors obtainable from cell-free synthesis and process for obtaining cedna vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023116157A Division JP2023126487A (ja) 2018-01-19 2023-07-14 無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス

Publications (2)

Publication Number Publication Date
JP2021511047A true JP2021511047A (ja) 2021-05-06
JP2021511047A5 JP2021511047A5 (https=) 2022-02-24

Family

ID=67301565

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020539779A Pending JP2021511047A (ja) 2018-01-19 2019-01-18 無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス
JP2023116157A Withdrawn JP2023126487A (ja) 2018-01-19 2023-07-14 無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス
JP2025084944A Pending JP2025113389A (ja) 2018-01-19 2025-05-21 無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023116157A Withdrawn JP2023126487A (ja) 2018-01-19 2023-07-14 無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス
JP2025084944A Pending JP2025113389A (ja) 2018-01-19 2025-05-21 無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス

Country Status (16)

Country Link
US (1) US12442015B2 (https=)
EP (1) EP3740571A4 (https=)
JP (3) JP2021511047A (https=)
KR (2) KR20250159738A (https=)
CN (1) CN111868242A (https=)
AU (1) AU2019210034B2 (https=)
BR (1) BR112020013319A2 (https=)
CA (1) CA3088984A1 (https=)
IL (1) IL275878B2 (https=)
MA (1) MA51626A (https=)
MX (1) MX2020005790A (https=)
MY (1) MY208589A (https=)
PH (1) PH12020550878A1 (https=)
SG (1) SG11202005271TA (https=)
UA (1) UA130154C2 (https=)
WO (1) WO2019143885A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506771A (ja) * 2018-11-09 2022-01-17 ジェネレーション バイオ カンパニー 対称的な修飾型逆位末端反復配列を含む修飾型閉端ｄｎａ（ｃｅｄｎａ）

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ762100A (en) 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
KR20200120649A (ko) * 2018-02-14 2020-10-21 제너레이션 바이오 컴퍼니 비-바이러스 dna 벡터 및 항체 및 융합 단백질 생산을 위한 이의 용도
EP3833766A1 (en) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
GB201905651D0 (en) 2019-04-24 2019-06-05 Lightbio Ltd Nucleic acid constructs and methods for their manufacture
CA3147414A1 (en) 2019-07-17 2021-01-21 Generation Bio Co. Synthetic production of single-stranded adeno associated viral dna vectors
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20230138409A1 (en) * 2020-03-24 2023-05-04 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
JP2023535632A (ja) 2020-07-27 2023-08-18 アンジャリウム バイオサイエンシズ エージー Ｄｎａ分子の組成物、その作製方法、及びその使用方法
US20220243201A1 (en) * 2020-08-23 2022-08-04 Bioverativ Therapeutics Inc. Engineered itr sequences and methods of use
EP4214309A4 (en) * 2020-09-16 2025-07-16 Generation Bio Co CLOSED-END DNA VECTORS AND RELATED USES FOR EXPRESSING PHENYLALANINE HYDROXYLASE (PAH)
GB202014751D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Targeting vector
GB202014772D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Nucleic acid construct
US20240100132A1 (en) * 2021-01-25 2024-03-28 Prevail Therapeutics, Inc. Modulation of aav-based gene expression
CN112980862A (zh) * 2021-02-25 2021-06-18 通用生物系统（安徽）有限公司 一种高纯度微环dna的制备方法
JP2024517427A (ja) 2021-04-20 2024-04-22 アンジャリウム バイオサイエンシズ エージー アミロ－α－１，６－グルコシダーゼ、４－α－グルカノトランスフェラーゼをコードするＤＮＡ分子の組成物、その作製の方法、及びその使用の方法
US20240216535A1 (en) * 2021-04-27 2024-07-04 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
AU2022264509A1 (en) * 2021-04-27 2023-12-14 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
KR20240005903A (ko) * 2021-05-07 2024-01-12 제너레이션 바이오 컴퍼니 백신 전달을 위한 비바이러스성 dna 벡터
CA3218126A1 (en) * 2021-05-07 2022-11-10 Matthew MANGANIELLO Lyophilized non-viral dna vector compositions and uses thereof
AU2022422134A1 (en) * 2021-12-23 2024-07-04 Generation Bio Co. Scalable and high-purity cell-free synthesis of closed-ended dna vectors
JP2025504404A (ja) 2022-01-14 2025-02-12 アンジャリウム バイオサイエンシズ エージー Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法
GB202204112D0 (en) 2022-03-23 2022-05-04 Lightbio Ltd Linear construct
EP4293101A1 (en) 2022-06-14 2023-12-20 Asklepios Biopharmaceutical, Inc. Reactor with temperature control and method of using the same
CA3262218A1 (en) 2022-07-19 2024-01-25 Rampart Bioscience, Inc. CIRCULAR NON-IMMUNOGENEOUS NON-VIRAL DNA VECTORS
US20260055426A1 (en) 2022-08-19 2026-02-26 Generation Bio Co. CLEAVABLE CLOSED-ENDED DNA (ceDNA) AND METHODS OF USE THEREOF
KR20250129818A (ko) * 2022-12-01 2025-08-29 제너레이션 바이오 컴퍼니 합성 단일-가닥 dna 분자 및 이를 생산하고 사용하는 방법
EP4665865A1 (en) 2023-02-17 2025-12-24 Anjarium Biosciences AG Methods of making dna molecules and compositions and uses thereof
US11993783B1 (en) * 2023-03-27 2024-05-28 Genecraft Inc. Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof
WO2026085495A1 (en) 2024-10-18 2026-04-23 Generation Bio Co. Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010046066A (ja) * 2007-08-10 2010-03-04 Toto Ltd 組換え哺乳動物細胞、組換え哺乳動物細胞の製造方法、および目的タンパク質の生産方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US6346415B1 (en) * 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
CA2467647A1 (en) 2001-11-30 2003-06-05 Innogenetics N.V. Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma
US8709778B2 (en) * 2008-10-28 2014-04-29 Xavier Danthinne Method of adenoviral vector synthesis
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
WO2014143932A1 (en) * 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Synthetic adeno-associated virus inverted terminal repeats
MX2018010633A (es) * 2016-03-03 2019-06-13 Univ Massachusetts Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral.
JP7026248B2 (ja) 2017-11-21 2022-02-25 ４ベースバイオ ソシエダー リミターダ 二本鎖ｄｎａを増幅するための方法およびキット
KR20200120649A (ko) * 2018-02-14 2020-10-21 제너레이션 바이오 컴퍼니 비-바이러스 dna 벡터 및 항체 및 융합 단백질 생산을 위한 이의 용도
JP2022518504A (ja) * 2019-01-24 2022-03-15 ジェネレーション バイオ カンパニー 閉端ｄｎａ（ｃｅｄｎａ）ならびに遺伝子療法または核酸療法に関連する免疫応答を低減させる方法における使用
CA3147414A1 (en) * 2019-07-17 2021-01-21 Generation Bio Co. Synthetic production of single-stranded adeno associated viral dna vectors
CA3146966A1 (en) * 2019-07-17 2021-01-21 Generation Bio Co. Compositions and production of nicked closed-ended dna vectors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010046066A (ja) * 2007-08-10 2010-03-04 Toto Ltd 組換え哺乳動物細胞、組換え哺乳動物細胞の製造方法、および目的タンパク質の生産方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GENE THER. 2013, VOL.20, NO.6, PP.686-693, JPN6023006400, ISSN: 0005543988 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506771A (ja) * 2018-11-09 2022-01-17 ジェネレーション バイオ カンパニー 対称的な修飾型逆位末端反復配列を含む修飾型閉端ｄｎａ（ｃｅｄｎａ）
JP7590963B2 (ja) 2018-11-09 2024-11-27 ジェネレーション バイオ カンパニー 対称的な修飾型逆位末端反復配列を含む修飾型閉端ｄｎａ（ｃｅｄｎａ）

Also Published As

Publication number Publication date
UA130154C2 (uk) 2025-12-03
MY208589A (en) 2025-05-19
EP3740571A4 (en) 2021-12-08
PH12020550878A1 (en) 2021-04-05
KR102879598B1 (ko) 2025-11-03
RU2020127017A (ru) 2022-02-21
MA51626A (fr) 2020-11-25
JP2025113389A (ja) 2025-08-01
BR112020013319A2 (pt) 2020-12-01
US20210071197A1 (en) 2021-03-11
IL275878B2 (en) 2026-03-01
IL275878B1 (en) 2025-11-01
WO2019143885A1 (en) 2019-07-25
KR20200111726A (ko) 2020-09-29
MX2020005790A (es) 2020-10-28
EP3740571A1 (en) 2020-11-25
JP2023126487A (ja) 2023-09-07
CN111868242A (zh) 2020-10-30
IL275878A (en) 2020-08-31
KR20250159738A (ko) 2025-11-11
AU2019210034A1 (en) 2020-07-09
US12442015B2 (en) 2025-10-14
AU2019210034B2 (en) 2025-03-27
SG11202005271TA (en) 2020-07-29
CA3088984A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
JP2023126487A (ja) 無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス
JP2022190081A (ja) 修飾型閉端ｄｎａ（ｃｅｄｎａ）
JP7590963B2 (ja) 対称的な修飾型逆位末端反復配列を含む修飾型閉端ｄｎａ（ｃｅｄｎａ）
JP2021505159A (ja) 修飾型閉端ｄｎａ（ｃｅｄｎａ）を使用する遺伝子編集
JP7583732B2 (ja) フェニルアラニンヒドロキシラーゼ（ｐａｈ）治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用
JP2022520803A (ja) 閉端ＤＮＡ（ｃｅＤＮＡ）の産生におけるＲＥＰタンパク質活性の調節
JP2021513999A (ja) 閉端ｄｎａ（ｃｅｄｎａ）ベクターを使用した導入遺伝子の制御された発現
AU2020315444A1 (en) Synthetic production of single-stranded adeno associated viral DNA vectors
EP3999646A1 (en) Compositions and production of nicked closed-ended dna vectors
JP2024511026A (ja) Ｐｆｉｃ治療薬を発現させるための非ウイルス性ｄｎａベクター及びその使用
JP2023520763A (ja) ゴーシェ治療薬を発現するための非ウイルス性ｄｎａベクター及びその使用
JP2022523806A (ja) 閉端ｄｎａ（ｃｅｄｎａ）および免疫調節化合物
CN116507730A (zh) 封闭端dna载体及其用于表达苯丙氨酸羟化酶（pah）的用途
US20250049961A1 (en) Scalable and high-purity cell-free synthesis of closed-ended dna vectors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241220